NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
MWN-AI** Summary
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) has announced three important presentations at the upcoming 2026 American College of Cardiology Annual Scientific Session (ACC.26), scheduled for March 28-30 in New Orleans. The presentations will focus on obicetrapib, a novel, oral, low-dose CETP inhibitor aimed at treating hypercholesterolemia in patients at risk for cardiovascular disease where current treatments have limitations.
The first presentation, titled "CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial," will be given by Dr. John Kastelein on March 28 from 3:30 - 3:37 PM CDT. The second presentation, "Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis," will follow on March 29 at 10:18 AM CDT, presented by Dr. Adam Nelson. Lastly, Dr. Floriaan Schmidt will present findings on the significance of small/medium LDL particles in cardiovascular risk on March 30 at 11:00 AM CDT.
Obicetrapib has shown promise in previous clinical trials, including significant LDL-lowering effects and a favorable safety profile akin to placebo. NewAmsterdam has also commenced the Phase 3 PREVAIL trial to explore obicetrapib’s efficacy in reducing major adverse cardiovascular events (MACE), with over 9,500 patients enrolled.
The company aims to fulfill an unmet medical need for safe and effective LDL-lowering therapies for patients who have not adequately responded to existing treatments. Commercialization rights for obicetrapib in Europe have been granted to Italy's Menarini Group, emphasizing the broader reach and potential impact of this innovative therapy.
MWN-AI** Analysis
NewAmsterdam Pharma's recent announcements regarding its presentations at the 2026 American College of Cardiology Annual Scientific Session reveal promising developments in the cardiovascular pharmaceutical landscape. The company presents its investigational oral CETP inhibitor, obicetrapib, aimed at lowering LDL cholesterol in patients inadequately served by current therapies.
With presentations scheduled from March 28 to March 30, key topics include the preservation of kidney function in high-risk cardiovascular patients and a safety analysis from pooled Phase III trials. Sharing data on how obicetrapib demonstrates significant LDL-lowering effects comparable to placebo side effects will likely create a favorable perception among healthcare professionals and investors alike. The outcomes of these presentations could receive heightened attention, especially given the pivotal role of cholesterol management in cardiovascular health.
For investors, the critical takeaway is that NewAmsterdam's continued focus on unmet needs in cardiovascular care may offer considerable potential. The Phase 3 PREVAIL trial, with enrollment of over 9,500 patients, adds credibility to its approach and could lead to transformative market positioning upon successful results. Moreover, its exclusive commercialization agreement with Menarini in Europe may bolster revenue prospects once the drug receives regulatory approvals.
It is essential to observe market reactions post-presentation, as positive findings could result in an uptick in stock performance. Conversely, any negative feedback or unexpected data from the presentations could lead to volatility. Therefore, maintaining a balanced investment strategy, including potential hedging, might be prudent as NewAmsterdam Pharma navigates this critical phase in its development and potential market entry for obicetrapib. As the cardiovascular market evolves, keeping abreast of regulatory news and competitive therapies will be vital for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the at the American College of Cardiology Annual Scientific Session (ACC.26), taking place on March 28-30 in New Orleans, Louisiana.
Presentation details are as follows:
Presentation Title: CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial
Session Title: 1069: Next-Generation Lipid Treatment Options
Digital Poster Presentation Date and Time: Saturday, March 28, 2026, 3:30 - 3:37 PM CDT
Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma
Location: Moderated Poster Theater 06, Posters, Hall E
Presentation Title: Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis
Session Title: 1084: Evolving Non-Statin Therapies
Digital Poster Presentation Date and Time: Sunday, March 29, 2026, 10:18 - 10:25 AM CDT
Presenter: Adam Nelson, Ph.D.
Location: Moderated Poster Theater 05, Posters, Hall E
Presentation Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles
Session Title: 1180: Linking Lipid Metrics to CVD Risks
Digital Poster Presentation Date and Time: Monday, March 30, 2026, 11:00 - 11:07 AM CDT
Presenter: Floriaan Schmidt, Ph.D.
Location: Moderated Poster Theater 05, Posters, Hall E
About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ**
How does NewAmsterdam Pharma Company N.V. plan to leverage the findings from the BROADWAY trial of obicetrapib to impact the market for LDL-lowering therapies, especially in relation to their warrant NAMSW?
What strategies is NewAmsterdam Pharma Company N.V. employing to ensure that obicetrapib effectively addresses the unmet needs of patients with elevated LDL-C, considering their warrant NAMSW in future funding rounds?
Given the ongoing developments in cardiovascular medications, what challenges does NewAmsterdam Pharma Company N.V. anticipate in the commercialization of obicetrapib, and how might this affect investor sentiment regarding NAMSW?
How important will the data presented at the ACC.26 conference be for NewAmsterdam Pharma Company N.V. in securing further investment in their warrant NAMSW and supporting the launch of obicetrapib?
**MWN-AI FAQ is based on asking OpenAI questions about NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW).
NASDAQ: NAMSW
NAMSW Trading
-5.65% G/L:
$18.20 Last:
1,218 Volume:
$19.29 Open:
NAMSW Latest News
